Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of alpelisib, an alpha-specific PI3K inhibitor, and trastuzumab, a HER2-targeted monoclonal antibody. This combination targets both the PI3K pathway and HER2 receptor to overcome resistance mechanisms in breast cancer, particularly in patients with PIK3CA mutations. The combination has shown synergistic effects in preclinical studies and is being evaluated in clinical trials for HER2-positive PIK3CA-mutated advanced breast cancer.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on alpelisib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + trastuzumab.